ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope

Molecular Cancer Therapeutics

Volumn 15, Issue 4, 2016, Pages 661-669

  Phillips, Andrew C ^a   Boghaert, Erwin R ^a   Vaidya, Kedar S ^a   Mitten, Michael J ^a   Norvell, Suzanne ^b   Falls, Hugh D ^a   Devries, Peter J ^a   Cheng, Dong ^a   Meulbroek, Jonathan A ^a   Buchanan, Fritz G ^a   McKay, Laura M ^a   Goodwin, Neal C ^c   Reilly, Edward B ^a  

^a ABBVIE INC   (United States)

^b TKIS   (United States)

^c JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEPATUXIZUMAB; DEPATUXIZUMAB MAFODOTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; TEMOZOLOMIDE; VEDOTIN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY; FEMALE; GENE DELETION; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CARCINOMA; MOLECULARLY TARGETED THERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RECEPTOR DENSITY; REPEATED DRUG DOSE; SQUAMOUS CELL LUNG CARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY AFFINITY; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOLOGY; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODY AFFINITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOCONJUGATES; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964318484     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0901     Document Type: Article

References (41)

1. Burgess AW. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008;26:263-74.
2. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85.
3. Enrique AA, Gema PC, Jeronimo JC, Auxiliadora GE. Role of anti-EGFR target therapy in colorectal carcinoma. Front Biosci 2012;4:12-22.
4. Landi L, Cappuzzo F. Pharmacotherapy targeting the EGFR oncogene in NSCLC. Expert Opin Pharmacother 2014;15:2293-305.
5. Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013;19:1389-400.
6. Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, et al. Antibodydrug conjugates: an emerging modality for the treatment of cancer. AnnNY Acad Sci 2014;1321:41-54.
7. Okeley NM, Alley SC, Senter PD. Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug. Hematol Oncol Clin North Am 2014;28:13-25.
8. Baron JM, Boster BL, Barnett CM. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. J Oncol Pharm Pract 2015;21:132-42.
9. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009;4:107-19.
10. Gan HK, Burgess AW, Clayton AH, Scott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 2012;72:2924-30.
11. Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, et al. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Mol Cancer Ther 2015;14:1141-51.
12. Cleary JM, Reardon DA, Azad N, Gandhi L, Shapiro GI, Chaves J, et al. A phase 1 study of ABT-806 in subjects with advanced solid tumors. Invest New Drugs 2015;33:671-8.
13. Sharma S, Mittapalli RK, Holen KD, Xiong H. Population pharmacokinetics of ABT-806, an investigational anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in advanced solid tumor types likely to either over-express wild-type EGFR or express variant III mutant EGFR. Clin Pharmacokinet 2015;54:1071-81.
14. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14.
15. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, et al. Epidermal growth factor receptor-targeted therapywith C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7:1204-13.
16. Yang BB, Lum P, Chen A, Arends R, Roskos L, Smith B, et al. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet 2010;49:729-40.
17. Doronina SO, Bovee TD, Meyer DW, Miyamoto JB, Anderson ME, Morris-Tilden CA, et al. Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem 2008;19:1960-3.
18. Henson JW. Treatment of glioblastomamultiforme: a new standard. Archiv Neurol 2006;63:337-41.
19. Blumenthal DT, Schulman SF. Survival outcomes in glioblastoma multiforme, including the impact of adjuvant chemotherapy. Expert Rev Neurother 2005;5:683-90.
20. Gan HK, Fichtel L, Lassman AB, Merrell R, Van Den Bent MJ, Kumthekar P, et al. A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM). J Clin Oncol 2014;35:2021.
21. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114-24.
22. Garrett TP, Burgess AW, Gan HK, Luwor RB, Cartwright G, Walker F, et al. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A 2009;106:5082-7.
23. Merlino GT, Ishii S, Whang-Peng J, Knutsen T, Xu YH, Clark AJ, et al. Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol Cell Biol 1985;5:1722-34.
24. Merlino GT, Xu YH, Richert N, Clark AJ, Ishii S, Banks-Schlegel S, et al. Elevated epidermal growth factor receptor gene copy number and expression in a squamous carcinoma cell line. J Clin Invest 1985;75:1077-9.
25. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65:226-35.
26. Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 2009;8:2042-50.
27. Boghaert ER, Khandke K, Sridharan L, Armellino D, Dougher M, Dijoseph JF, et al. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. Int J Oncol 2006;28:675-84.
28. Heneweer C, Holland JP, Divilov V, Carlin S, Lewis JS. Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system. J Nuclear Med 2011;52:625-33.
29. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011;63:136-51.
30. Filmus J, Pollak MN, Cailleau R, Buick RN. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 1985;128:898-905.
31. Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A 2007;104:4071-6.
32. Gan HK, Burge ME, Solomon BJ, Holen KH, Zhang Y, Ciprotti M, et al. A phase I and biodistribution study of ABT-806i, an 111indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806. J Clin Oncol 31, 2013(suppl; abstr 2520).
33. The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576-82.
34. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
35. Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, et al. ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). J Clin Oncol 2015;33:2510.
36. Khattri A, Zuo Z, Bragelmann J, Keck MK, El Dinali M, Brown CD, et al. Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncol 2015;51:53-8.
37. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12:5064-73.
38. Sasaki H, Kawano O, Endo K, Yukiue H, Yano M, Fujii Y. EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. Oncol Rep 2007;17:319-23.
39. Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, et al. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol 2005;27:317-25.
40. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995;55:3140-8.
41. Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, et al. AMG595, an anti-EGFRvIII antibody-drug conjugate, induces potent antitumor activity against EGFRvIII-expressing glioblastoma. Mol Cancer Ther 2015;14:1614-24.